Dr. Michael Rauh received funding from the AFP Innovation Fund entitled 2012 March 19 "Towards earlier detection and personalized diagnosis in Myelodysplastic Syndromes (MDS): a SEAMO-driven initiative of the Canadian MDS Consortium".
Myelodysplastic syndromes (MDS) are blood cancers that cause debilitating and life-threatening bleeding, infections, and transfusion-dependence, often transforming to acute leukemia. MDS primarily afflicts older adults but diagnosis is commonly delayed because of limited detection tools that lag behind genetic advances. Faced with our aging population and newly available effective forms of treatment, earlier MDS detection and methods to tailor patient-specific therapy are direly needed.
rauh2012mar
|